Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

This letter explores off-label dosing adjustments for patients with psoriasis using the IL-17A inhibitors secukinumab and ixekizumab.

Dose Escalation of IL-17A Inhibitors for Psoriasis Effective, Though Risks Remain

In this study, investigators assessed how the prescription patterns of biologics, non-biologic systemic agents, and phototherapy are altered after cardiovascular events.

Patients with Psoriasis on Biologics More Likely to Continue Use Following MACE

These data underscore the value of individualized cancer risk evaluations when selecting treatment strategies for psoriasis.

Biologic Therapy is Associated with Reduced Risk of Malignancy in Psoriasis

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.

EADV Congress 2025: Late-Breaking Trials Preview

Investigators systematically reviewed NB-UVB treatment responses for psoriasis in patients with skin of color.

Narrowband-UVB Phototherapy Effective for Psoriasis in Skin of Color

In this observational analysis, investigators highlight the potential causal link identified between NHHR and psoriasis development.

Non-High-Density to High Density Lipoprotein Cholesterol Ratio Linked with Psoriasis

An audio recap of the top 5 stories in healthcare news from the week of 08/31-9/5.

HCPLive 5 Stories in Under 5: Week of 08/31

Investigators highlighted the cardiovascular safety of systemic treatments for psoriasis such as methotrexate and tumor necrosis factor inhibitors.

Methotrexate, TNF Inhibitors Are Safest Psoriasis Drugs for Cardiovascular Risk

This analysis highlights bimekizumab’s impact on psoriasis clearance compared to ustekinumab, secukinumab, and adalimumab.

Bimekizumab Outperforms Active Comparators in Clearing Skin, Nail Psoriasis

This announcement regarding the new sNDA for roflumilast cream in pediatric patients with psoriasis follows positive findings from the MUSE study.

Arcutis Submits sNDA for Roflumilast Cream 0.3% for Psoriasis in Children Aged 2-5 Years

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Plaque Psoriasis